This vaccine produced a reduction of tumor growth in vitro and the immunological response was T CD8+ dependent and T CD4+-independent, suggesting that HPV16 E5 is an antigen able to induce tumor rejection [117]. The gene discussed is CD8A; the disease is neoplasm.